Company: BDRX
Filing Date: 2025-12-11
Form Type: F-1/A
Source: 0001214659-25-017944
Chunk: 149

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-12-11
Form: F-1/A
Chunk 149
---
 from the SEC at the address listed above or from the SEC’s website.

<div align='center'>INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</div>

The SEC allows us to “incorporate
by reference” the information we file with the SEC, which means that we can disclose important information to you by referring you
to another document filed separately with the SEC. The information incorporated by reference is an important part of this prospectus.
We incorporate by reference, as of their respective dates of filing, the documents listed below that we have filed with the SEC and any
documents that we file with the SEC pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act after the date of this prospectus
and prior to the termination of the offering of securities under this prospectus (except in each case the information contained in such
documents to the extent “furnished” and not “filed”):

| 89 |

We are also incorporating
by reference all subsequent Annual Reports on Form 20-F that we file with the SEC and certain reports on Form 6-K that we furnish to the
SEC after the date of this prospectus (if they state that they are incorporated by reference into this prospectus) prior to the termination
of this offering. In all cases, you should rely on the later information over different information included in this prospectus or any
accompanying prospectus supplement.

Unless expressly incorporated
by reference, nothing in this prospectus shall be deemed to incorporate by reference information furnished to, but not filed with, the
SEC. Copies of all documents incorporated by reference in this prospectus, other than exhibits to those documents unless such exhibits
are specifically incorporated by reference in this prospectus, will be provided at no cost to each person, including any beneficial owner,
who receives a copy of this prospectus on the written or oral request of that person made to:

<div align='center'>Biodexa Pharmaceuticals PLC

1 Caspian Point

Caspian Way

Cardiff, CF10 4DQ, United Kingdom

+44 29 2048 0180</div>

You may also access these
documents on our website, www.biodexapharma.com. The information contained on, or that can be accessed through, our website
is not a part of this prospectus. We have included our website address in this prospectus solely as an inactive textual reference.

You should rely only on information